P152 Fatty liver disease in IBD patients as a part of extraintestinal manifestations
A. Atanassova*1, A. Georgieva2
1Medical University Varna, Clinic of Hepatogastroenterology, St. Marina University Hospital, Varna, Bulgaria, 2Medical University Varna, Clinic of Hepatogastroenterology, St. Marina University Hospital, Vаrna, Bulgaria
Inflammatory bowel diseases (IBD) are frequently associated with pathologic findings in the liver and biliary tract, ranging from minor alterations, such as liver fatty changes, to severe conditions, like primary sclerosing cholangitis.1 Fatty liver disease (FLD) is the most common liver complication of IBD and is often reversible, affecting people with ulcerative colitis (UC) and Crohn’s disease (CD).
The aim of the study was to investigate the incidence of hepatic steatosis as a part of the extraintestinal manifestations (EIMs) in IBD patients and the related biochemical laboratory abnormalities. A total of 480 patients was studied, 160 with UC, and 160 with CD and the results were compared with those of a control group of 160 patients with irritable bowel syndrome (IBS). An abdominal ultrasound (AUS) was performed on all of them as a non-invasive method of assessing the presence and the degree of liver steatosis, in combination with the liver function tests (LFTs), lipid and glycaemic profile blood tests.
Of all the studied IBD patients, hepatic steatosis based on AUS criteria was discovered in 59.4% with CD and in 51.9% with UC. In the control group steatosis was found in 38.8% of cases (
The incidence of hepatic steatosis is higher amongst IBD patients. We need further studies to determine the influence that the evolution of IBD has over the hepatic steatosis.